Longevity Medical Institute launches intranasal regenerative neurology platform

Longevity Medical Institute in San José del Cabo launched a regenerative neurology program built around an intranasal nose-to-brain delivery system as a less invasive alternative to intrathecal administration for selected patients. The platform is designed to support personalized treatment planning for neurological conditions while broader clinical trials continue to define who benefits most.

Why it matters: - Longevity Medical Institute is expanding treatment options for neurological disorders with a non-invasive delivery route that may reduce the need for lumbar puncture. - The new platform is intended for selected patients when physicians determine intranasal delivery is clinically appropriate. - The launch reflects growing interest in regenerative neurology as a translational medicine field.

What happened: - Longevity Medical Institute launched its Regenerative Neurological Therapy Program on July 23, 2026, in San José del Cabo, Baja California Sur, Mexico. - The program centers on an advanced intranasal delivery platform designed to transport regenerative therapies toward the brain through the nasal cavity. - The institute positioned the platform as an alternative to intrathecal administration for certain neurological conditions. - Dr. Kirk Sanford, founder and CEO of Longevity Medical Institute, said the new platform expands the institute’s ability to personalize treatment.

The details: - The blood-brain barrier blocks many therapeutic compounds from reaching the central nervous system. - Intrathecal administration remains the most direct route for delivering regenerative therapies into cerebrospinal fluid, but it requires a lumbar puncture. - The intranasal platform targets the upper nasal cavity near the olfactory region rather than the lower nasal passages. - Research has shown that compounds delivered to the olfactory region may travel toward the brain along the olfactory and trigeminal nerve pathways. - The system uses an electronically controlled nebulizer instead of a traditional spray pump. - The nebulizer generates microscopic aerosol droplets and delivers them gradually over several minutes. - The design is intended to increase contact time in the olfactory region, reduce medication loss into the throat, and improve delivery consistency. - Longevity Medical Institute uses the platform only for regenerative therapies, including mesenchymal stem cells, MSC-derived exosomes, and selected therapeutic peptides. - Physicians recommend treatment after a comprehensive neurological evaluation that may include advanced imaging, laboratory testing, neurological examination, and review of medical history. - The broader neurological program also includes intravenous regenerative therapies, intrathecal administration in the institute’s fully licensed operating room when indicated, hyperbaric oxygen therapy, advanced neurological imaging, and multidisciplinary physician care. - The institute said treatment recommendations are based on physician evaluation, published scientific evidence, patient-specific factors, and clinical judgment. - The institute’s website for more information is More information.

Between the lines: - The launch pairs a less invasive delivery method with an evidence-based framing meant to support physician-guided customization. - Published human research on MSCs and MSC-derived exosomes has reported encouraging findings across conditions including ischemic stroke, multiple sclerosis, ALS, spinal cord injury, Parkinson’s disease, Alzheimer’s disease, traumatic brain injury, cerebral palsy, and other neurodegenerative disorders. - Across published studies, researchers have reported a favorable safety profile while evaluating possible improvements in neurological function, disease stabilization, walking ability, cognitive performance, quality of life, and neuroinflammation. - The institute acknowledged that larger randomized clinical trials are still needed to determine which patients benefit most and how durable treatment responses may be. - Dr. Sanford said the institute aims to combine scientific evidence with advanced diagnostics and physician-guided treatment planning.

What’s next: - Longevity Medical Institute expects the intranasal platform to work alongside intrathecal and intravenous options as physicians match delivery method to diagnosis and treatment goals. - Further clinical research will be needed to clarify patient selection and durability of response. - The institute said regenerative neurological therapies remain one of the fastest-growing areas of translational medicine.

The bottom line: - Longevity Medical Institute is betting that a controlled intranasal delivery system can broaden access to regenerative neurology while keeping treatment decisions individualized and clinically guided.